KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) EBIT Margin (2016 - 2026)

Eli Lilly filings provide 18 years of EBIT Margin readings, the most recent being 47.98% for Q1 2026.

  • On a quarterly basis, EBIT Margin rose 660.0% to 47.98% in Q1 2026 year-over-year; TTM through Mar 2026 was 46.29%, a 787.0% increase, with the full-year FY2025 number at 44.82%, up 890.0% from a year prior.
  • EBIT Margin hit 47.98% in Q1 2026 for Eli Lilly, up from 46.15% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 47.98% in Q1 2026 to a low of 22.97% in Q1 2023.
  • Median EBIT Margin over the past 5 years was 34.23% (2024), compared with a mean of 35.15%.
  • Biggest five-year swings in EBIT Margin: plummeted -993bps in 2023 and later surged 1150bps in 2025.
  • Eli Lilly's EBIT Margin stood at 28.44% in 2022, then rose by 13bps to 32.18% in 2023, then rose by 23bps to 39.44% in 2024, then increased by 17bps to 46.15% in 2025, then increased by 4bps to 47.98% in 2026.
  • The last three reported values for EBIT Margin were 47.98% (Q1 2026), 46.15% (Q4 2025), and 45.57% (Q3 2025) per Business Quant data.